Obrero-Gaitán Esteban, Cortés-Pérez Irene, Calet-Fernández Tania, García-López Héctor, López Ruiz María Del Carmen, Osuna-Pérez María Catalina
Department of Health Sciences, University of Jaén, Campus Las Lagunillas s/n, 23071 Jaén, Spain.
Clínica Vitaudio Linares, Baños Street 16, 23700 Linares, Spain.
Cancers (Basel). 2022 Aug 26;14(17):4133. doi: 10.3390/cancers14174133.
Digital and interactive health interventions (DIHIs), such as virtual-reality-based therapy (VRBT) and smartphone-app-based therapy (SABT), may be useful for reducing the impact of the signs and symptoms of breast cancer (BC) in women. The aim of this meta-analysis was to explore the effect of DIHIs on improving pain, anxiety, depression, quality of life (QoL), and upper extremity (UE) disability-related lymphedema in women with BC.
We searched PubMed Medline, Web of Science, Scopus, CINAHL, Physiotherapy Evidence Database, and SciELO for the period ending February 2022. We included studies that assessed the effect of DIHIs on UE motor disability, pain, anxiety, depression, and QoL in women with BC. The effect size was calculated using Cohen's standardized mean difference (SMD) and its 95% confidence interval (95% CI).
Twenty studies providing data from 1613 women with BC were included. With respect to UE disability, DIHIs increased flexion (SMD, 1.92; 95%CI: -1.16, 2.68), abduction (SMD, 1.66; 95%CI: 0.91, 2.42), external rotation shoulder range of motion (SMD, 1.1; 95%CI: 0.36, 1.85), UE function (SMD, -0.72; 95%CI: -1.31, -0.13), and handgrip strength (SMD, 0.4; 95%CI: 0.21, 0.59). DIHIs reduced pain (SMD, -0.8; 95%CI: -1.31, -0.26), anxiety (SMD, -1.02; 95%CI: -1.71, -0.34), and depression (SMD, -1.57; 95%CI: -3.1, -0.08). Finally, DIHIs increased overall health (SMD, 0.6; 95%CI: 0.31, 0.89).
Right at the end of therapy, DIHIs are effective at improving UE function, pain, anxiety, depression, and QoL in women with BC. VRBT has a greater effect than SABT for the assessed outcomes.
数字和交互式健康干预措施(DIHIs),如基于虚拟现实的疗法(VRBT)和基于智能手机应用程序的疗法(SABT),可能有助于减轻女性乳腺癌(BC)体征和症状的影响。本荟萃分析的目的是探讨DIHIs对改善BC女性疼痛、焦虑、抑郁、生活质量(QoL)以及与上肢(UE)残疾相关的淋巴水肿的效果。
我们检索了截至2022年2月的PubMed Medline、Web of Science、Scopus、CINAHL、物理治疗证据数据库和SciELO。我们纳入了评估DIHIs对BC女性UE运动残疾、疼痛、焦虑、抑郁和QoL影响的研究。使用Cohen标准化平均差(SMD)及其95%置信区间(95%CI)计算效应量。
纳入了20项为1613名BC女性提供数据的研究。关于UE残疾,DIHIs增加了屈曲(SMD,1.92;95%CI:-1.16,2.68)、外展(SMD,1.66;95%CI:0.91,2.42)、肩部外旋活动范围(SMD,1.1;95%CI:0.36,1.85)、UE功能(SMD,-0.72;95%CI:-1.31,-0.13)和握力(SMD,0.4;95%CI:0.21,0.59)。DIHIs减轻了疼痛(SMD,-0.8;95%CI:-1.31,-0.26)、焦虑(SMD,-1.02;95%CI:-1.71,-0.34)和抑郁(SMD,-1.57;95%CI:-3.1,-0.08)。最后,DIHIs提高了总体健康水平(SMD,0.6;95%CI:0.31,0.89)。
在治疗结束时,DIHIs能有效改善BC女性的UE功能、疼痛、焦虑、抑郁和QoL。对于所评估的结果,VRBT比SABT的效果更好。